MARKET

IMMP

IMMP

Immutep
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.810
+0.160
+5.97%
After Hours: 2.800 -0.01 -0.36% 16:51 02/21 EST
OPEN
2.690
PREV CLOSE
2.680
HIGH
2.850
LOW
2.680
VOLUME
197.19K
TURNOVER
--
52 WEEK HIGH
3.230
52 WEEK LOW
1.270
MARKET CAP
10.20M
P/E (TTM)
-0.7139
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of IMMP and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average IMMP stock price target is 5.41 with a high estimate of 6.89 and a low estimate of 3.935.

IMMP News

More
  • Immutep Reports Positive TACTI-002 Data
  • GlobeNewswire · 4d ago
  • The Daily Biotech Pulse: FDA Snub For Merck, Priority Review For Roche's Tecentriq sBLA
  • Benzinga · 4d ago
  • The Daily Biotech Pulse: FDA Snub For Merck, Priority Review For Roche's Tecentriq sBLA
  • Benzinga · 4d ago
  • The Week Ahead In Biotech: Agile, Baudax Bio, Merck and Esperion Await FDA Decisions
  • Benzinga · 02/16 20:03

Industry

Biotechnology & Medical Research
+0.37%
Pharmaceuticals & Medical Research
+0.54%

Hot Stocks

Symbol
Price
%Change
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%

About IMMP

Immutep Ltd, formerly Prima BioMed Ltd., is a biotechnology company. The Company is engaged in research, development and commercialization of licensed medical biotechnology. It is also focused on development of immunotherapeutic products. The Company operates through Cancer Immunotherapy segment. Its core technologies are based on the Lymphocyte-activation gene 3 (LAG-3) immune control mechanism, which is involved in regulation of the T cell immune response. Its product, IMP321, is in clinical development for the treatment of a range of cancer indications, such as Metastatic Breast Cancer. IMP321 is in Phase IIb trials for Metastatic Breast Cancer and is being studied in Phase I for the treatment of Metastatic Melanoma. The Company is also focused on development of other products, which include IMP701, an antibody for cancer, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer.
More

Webull offers kinds of Immutep Ltd stock information, including NASDAQ:IMMP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IMMP stock news, and many more online research tools to help you make informed decisions.